0001193125-21-161154 | 10-Q | XBRL Viewer | Ayala Pharmaceuticals INC

Cover Page - shares	3 Months Ended
Cover Page - shares	Mar. 31, 2021	May 01, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Period End Date	Mar. 31, 2021
Document Fiscal Period Focus	Q1
Current Fiscal Year End Date	--12-31
Document Quarterly Report	true
Document Transition Report	false
Entity Registrant Name	Ayala Pharmaceuticals, Inc.
Entity Central Index Key	0001797336
Entity Address, Country	IL
Entity Incorporation, State or Country Code	DE
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		13,240,961
Entity Shell Company	false
Title of 12(b) Security	Common Stock
Trading Symbol	AYLA
Security Exchange Name	NASDAQ

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and Cash Equivalents	$ 56,030	$ 42,025
Short-term Restricted Bank Deposits	117	90
Trade Receivables	169	681
Prepaid Expenses and other Current Assets	1,534	1,444
Total Current Assets	57,850	44,240
LONG-TERM ASSETS:
Other Assets	264	305
Property and Equipment, Net	1,119	1,283
Total Long-Term Assets	1,383	1,588
Total Assets	59,233	45,828
CURRENT LIABILITIES:
Trade Payables	3,004	3,726
Other Accounts Payables	2,690	3,151
Total Current Liabilities	5,694	6,877
LONG TERM LIABILITIES:
Long-term Rent Liability	505	553
Total Long-Term Liabilities	505	553
STOCKHOLDERS' STOCKHOLDERS' EQUITY:
Common Stock of $0.01 par value per share; 200,000,000 shares authorized at March 31, 2021 and December 31, 2020; 13,240,961 and 12,824,463 shares issued at March 31, 2021 and, respectively December 31, 2020; 13,072,213 and 12,728,446 shares outstanding at March 31, 2021 and December 31, 2020, respectively	131	128
Additional Paid-in Capital	133,358	109,157
Accumulated Deficit	(80,455)	(70,887)
Total Stockholders' Equity	53,034	38,398
Total Liabilities, Convertible Preferred Stock, and Stockholders' Equity	$ 59,233	$ 45,828

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2021	Dec. 31, 2020
Common stock par value	$ 0.01	$ 0.01
Common stock shares authorized	200,000,000	200,000,000
Common stock shares issued	13,240,961	12,824,463
Common stock shares outstanding	13,072,213	12,728,446

Condensed Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Statement of Comprehensive Income [Abstract]
Revenues from licensing agreement	$ 974	$ 1,001
Cost of Revenues	(974)	(1,001)
Gross profit	0	0
Operating expenses:
Research and development	6,925	5,128
General and administrative	2,303	1,311
Operating loss	(9,228)	(6,439)
Financial loss, net	(92)	(38)
Loss before income tax	(9,320)	(6,477)
Taxes on income	(248)	(121)
Net loss attributable to common stockholders	$ (9,568)	$ (6,598)
Net Loss per share attributable to common stockholders, basic and diluted	$ (0.74)	$ (1.32)
Weighted average common shares outstanding, basic and diluted	12,888,340	4,999,563

Condensed Consolidated Statements Of Changes In Convertible Preferred Stock And Stockholders' Equity - USD ($) $ in Thousands	Total	Preferred Stock [Member] Convertible Preferred Stock [Member]	Preferred Stock [Member] Convertible Preferred Stock [Member] Series A Preferred Stock [Member]	Preferred Stock [Member] Convertible Preferred Stock [Member] Series B Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Beginning balance, Preferred Stock , Shares at Dec. 31, 2019			3,679,778	3,750,674
Beginning balance, Preferred Stock at Dec. 31, 2019		$ 53,373	$ 23,823	$ 29,550
Ending balance, Preferred Stock , Shares at Mar. 31, 2020			3,679,778	3,750,674
Ending balance, Preferred Stock at Mar. 31, 2020		53,373	$ 23,823	$ 29,550
Beginning balance, Common Stock, Shares at Dec. 31, 2019					4,998,874
Beginning balance at Dec. 31, 2019	$ (38,920)				$ 51	$ 1,770	$ (40,741)
Share based compensation ,Shares					4,506
Share based compensation	293					293
Net Loss	(6,598)						(6,598)
Ending balance, Common Stock, Shares at Mar. 31, 2020					5,003,380
Ending Balance at Mar. 31, 2020	(45,225)				$ 51	2,063	(47,339)
Ending balance, Preferred Stock at Mar. 31, 2021
Beginning balance, Common Stock, Shares at Dec. 31, 2020					12,728,446
Beginning balance at Dec. 31, 2020	38,398				$ 128	109,157	(70,887)
Share based compensation ,Shares					4,434
Share based compensation	852					852
Exercise of stock options, Shares					6,000
Exercise of stock options	30					30
Issuance of shares and warrants, net of Issuance Cost of $1,665, Shares					333,333
Issuance of shares and warrants, net of Issuance Cost of $1,665	23,322				$ 3	23,319
Net Loss	(9,568)						(9,568)
Ending balance, Common Stock, Shares at Mar. 31, 2021					13,072,213
Ending Balance at Mar. 31, 2021	$ 53,034				$ 131	$ 133,358	$ (80,455)

Condensed Consolidated Statements Of Changes In Convertible Preferred Stock And Stockholders' Equity (Parenthetical) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Issuance of shares and warrants, net of Issuance Cost	$ 1,665

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (9,568)	$ (6,598)
Adjustments to reconcile net loss to net cash used in operating activities:
Shared based compensation	852	293
Depreciation	164	53
(Increase) decrease in Prepaid Expenses and Other Assets	(88)	115
(Increase) decrease in Trade Receivables	512	(532)
Increase (decrease) in Trade Payable	(1,012)	49
Increase in Long Term Rent Liability	0	249
Decrease in other Accounts Payable	(509)	(20)
Net Cash used in Operating Activities	(9,649)	(6,391)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from maturities of long-term deposits	0	202
Purchase of Equipment	0	(20)
Net Cash provided by Investing Activities	0	182
CASH FLOWS FROM FINANCING ACTIVITIES:
Deferred offering costs	0	(261)
Issuance of shares and warrants, Net	23,612	0
Exercise of stock options	30	0
Net Cash provided by (used in) Financing Activities	23,642	(261)
Increase (decrease) in Cash and Cash Equivalents and Restricted Bank Deposits	13,993	(6,470)
Cash and Cash Equivalents and Restricted Bank Deposits at Beginning of the period	42,370	16,808
Cash and Cash Equivalents and Restricted Bank Deposits at End of the period	56,363	10,338
SUPPLEMENTAL DISCLOSURE OF NON-CASH FINANCING ACTIVITIES
Non-cash deferred issuance costs.	290	1,133
Amortization of deferred rent liability	48	0
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Cash Received for Interest	3	24
Tax Paid in Cash, net of refunds	48	40
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]
Cash and Cash Equivalents	56,030	10,055
Restricted Bank Deposits	117	81
Restricted Bank Deposits in Other Assets	216	202
Cash and Cash Equivalents and Restricted Bank Deposits at End of the period	$ 56,363	$ 10,338

Significant Accounting Policies

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

Significant Accounting Policies

NOTE 1—SIGNIFICANT ACCOUNTING POLICIES

General

a) Ayala Pharmaceuticals, Inc. (the “Company”) was incorporated in November 2017. The Company is a clinical stage oncology company dedicated to developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The Company’s current portfolio of product candidates, AL101 and AL102, target the aberrant activation of the Notch pathway with gamma secretase inhibitors.

b) In 2017, the Company entered into an exclusive worldwide license agreement with respect to AL101 and AL102.

c) The Company’s lead product candidates, AL101 and AL102 have completed preclinical and Phase 1 studies. AL101 is currently being evaluated in a Phase 2 trial (ACCURACY) in patient with recurrent/metastatic adenoid cystic carcinoma (“R/M ACC”) bearing Notch-activating mutations and in a phase 2 trial (TENACITY) in patients with recurrent/metastatic triple negative breast cancer (“R/M TNBC”) bearing Notch-activating mutations.

d) The Company has a wholly-owned Israeli subsidiary, Ayala-Oncology Israel Ltd. (the “Subsidiary”), which was incorporated in November 2017.

e) Since inception, the Company has devoted its primary efforts to raising capital and research and development activities and has incurred significant operating losses and negative cash flows from operations. From its inception through March 31, 2021, all of the Company’s financial support has been provided primarily from the sale of its convertible preferred and common stock.

The Company previously identified conditions and events that raise substantial doubt about its ability to continue as a going concern. As a result of the completion of the Company’s initial public offering (“IPO”) in May 2020 and the Private Placement in February 2021, the Company believes that its cash, cash equivalents and short-term restricted bank deposits as of March 31, 2021 will be sufficient to fund its operating expenses and capital expenditure requirements into 2023. The Company has based this estimated on assumptions that may prove to be wrong, and it may use its available capital resources sooner than it currently expects. Future additional funding may not be available on terms available to the Company or at all. If the Company is unable to obtain sufficient funding, it could be required to delay its development efforts, limit activities and reduce research and development costs, which could adversely affect its business prospects.

Initial Public Offering and Related Transactions

On May 12, 2020, the Company completed the sale of shares of its common stock in its IPO. In connection with the IPO, the Company issued and sold 3,940,689 shares of common stock, including 274,022 shares associated with the partial exercise on June 4, 2020 of the underwriters’ option to purchase additional shares, at a price to the public of $15.00 per share, resulting in net proceeds to the Company of approximately $52.2 million after deducting underwriting discounts and commissions and offering expenses payable by the Company. All shares issued and sold were registered pursuant to a registration statement on Form

S-1

(File

No. 333-236942),

as amended, declared effective by the U.S. Securities and Exchange Commission (the “Commission”) on May 7, 2020.

In connection with the IPO, the Company effected a

one-for-two

reverse stock split of its common stock which became effective on May 4, 2020. Upon the closing of the IPO, all of the outstanding shares of Series A preferred stock and Series B preferred stock automatically converted into an aggregate of 3,715,222 shares of common stock. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding.

On February 19, 2021, the Company entered into a Securities Purchase Agreement (the “2021 Purchase Agreement”) with the purchasers named therein (the “Investors”). Pursuant to the 2021 Purchase Agreement, the Company agreed to sell (i) an aggregate of 333,333 shares of its common stock (the “Private Placement Shares”), par value $0.01 per share, together with warrants to purchase an aggregate of 116,666 shares of its common stock with an exercise price of $18.10 per share (the “Common Warrants”), for an aggregate purchase price of $4,999,995.00 and

(ii) pre-funded

warrants to purchase an aggregate of 1,333,333 shares of its common stock with an exercise price of $0.01 per share (the

“Pre-Funded

Warrants” and collectively with the Common Warrants, the “Private Placement Warrants”), together with an aggregate of 466,666 Common Warrants, for an aggregate purchase price of $19,986,661.67 (collectively, the “Private Placement”).

The Company had issuance costs of approximately $1,665 thousand of which $290 thousand was not yet paid due to payment terms. The Private Placement closed on February 23, 2021. The warrants were classified as a component of permanent equity pursuant to ASC 480 “Distinguishing Liabilities from Equity” and ASC 815 “Derivatives and Hedging”.

Basis of Presentation

The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”) for interim financial information. Accordingly, they do not include all of the information and notes required by GAAP for annual financial statements. In the opinion of management, all adjustments (of a normal recurring nature) considered necessary for a fair statement of the results for the interim periods presented have been included. Operating results for the interim period are not necessarily indicative of the results that may be expected for the full year.

These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form

10-K

filed for the year ended December 31, 2020 with the Commission. The comparative balance sheet at December 31, 2020 has been derived from the audited financial statements at that date. Except as noted below, the Company’s significant accounting policies have not changed materially from those included in Note 2 of the Company’s audited consolidated financial statements for the year ended December 31, 2020 included in the Company’s Annual Report on Form

10-K

for the year ended December 31, 2020.

Net Loss per Share

Basic and diluted loss per share (“LPS”) are computed by dividing net loss by the weighted average number of shares of the Company’s common stock, par value $0.01 per share (the “Common Stock”), outstanding for each period.

The calculation of diluted LPS does not include 3,679,778 shares of Series A Preferred Stock, and 3,750,674 shares of Series B Preferred Stock and 652,187 options outstanding to purchase common stock as of March 31, 2020.

The calculation of diluted LPS does not include 1,916,665 Warrants and 915,644 options outstanding to purchase common stock as of March 31 2021.

Newly Issued Accounting Pronouncements

As an “emerging growth company,” the Jumpstart Our Business Startups Act (“JOBS Act”) allows the Company to delay adoption of new or revised accounting pronouncements applicable to public companies until such pronouncements are made applicable to private companies. The Company has elected to use this extended transition period under the JOBS Act. The adoption dates discussed below reflects this election.

In February 2016, the FASB issued ASU

2016-02—Leases,

requiring the recognition of lease assets and liabilities on the balance sheet. The standard:

(a) clarifies the definition of a lease; (b) requires a dual approach to lease classification similar to current lease classifications; and (c)causes lessees to recognize leases on the balance sheet as a lease liability with a corresponding

right-of-use

asset for leases with a lease-term of more than 12 months. The standard is effective for public entities for fiscal years beginning after December 15, 2018 and for the Company for fiscal years beginning after December 15, 2021. The Company is currently evaluating the impact of adopting this new guidance on its financial statements.

In June 2016, the FASB issued ASU

No. 2016-13

(Topic 326), Financial Instruments—Credit Losses: Measurement of Credit Losses on Financial Instruments, which replaces the existing incurred loss impairment model with an expected credit loss model and requires a financial asset measured at amortized cost to be presented at the net amount expected to be collected. The guidance will be effective for the Company for fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company is currently evaluating the effect that ASU

2016-13

will have on its consolidated financial statements.

Revenues

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Revenues

NOTE 2—REVENUES

The Company recognizes revenue in accordance with ASC Topic 606, Revenue from Contracts with Customers, which applies to all contracts with customers. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps:

(i)

identify the contract(s) with a customer;

(ii)

identify the performance obligations in the contract;

(iii)

determine the transaction price;

(iv)

allocate the transaction price to the performance obligations in the contract; and

(v)

recognize revenue when (or as) the entity satisfies a performance obligation.

At contract inception, once the contract is determined to be within the scope of Topic 606, the Company assesses the goods or services promised within the contract and determines those that are performance obligations and assesses whether each promised good or service is distinct.

Customer option to acquire additional goods or services gives rise to a performance obligation in the contract only if the option provides a material right to the customer that it would not receive without entering into that contract.

In a contract with multiple performance obligations, the Company must develop estimates and assumptions that require judgment to determine the underlying stand-alone selling price for each performance obligation, which determines how the transaction price is allocated among the performance obligations.

The Company evaluates each performance obligation to determine if it can be satisfied at a point in time or over time.

Revenue is recognized when control of the promised goods or services is transferred to the customers, in an amount that reflects the consideration the Company expects to be entitled to receive in exchange for those goods or services.

In December 2018, the Company entered into an evaluation, option and license agreement (the “Novartis Agreement”) with Novartis International Pharmaceutical Limited (“Novartis”) for which the Company is paid for its research and development costs.

The Company concluded that there is one distinct performance obligation under the Novartis Agreement: Research and development services, an obligation which is satisfied over time.

Revenue associated with the research and development services in the amount of approximately

$1.0 million was recognized in the three months ended March 31, 2021.

The Company concluded that progress towards completion of the research and development performance obligation related to the Novartis Agreement is best measured in an amount proportional to the expenses relative to the total estimated expenses. The Company periodically reviews and updates its estimates, when appropriate, which may adjust revenue recognized for the period. The transaction price to be recognized as revenue under the Novartis Agreement consists of the reimbursable research and development costs.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-URI http://asc.fasb.org/topic&trid=49130388

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130551-203045

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130556-203045

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 9
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130550-203045

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130558-203045

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 12
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=121604090&loc=SL49130554-203045

+ Details

Tax

3 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Tax

NOTE 3—TAX

The change in provision for income taxes was

$137 thousand and $70 thousand for the three months ended March 31, 2021 and 2020, respectively. The Company’s effective tax rate differs from the U.S. federal statutory income tax rate of 21% primarily due to a full valuation allowance against the Company’s U.S. deferred tax asset in each period presented.

The Company has reviewed the tax positions taken, or to be taken, in its tax returns for all tax years currently open to examination by a taxing authority. As of March 31, 2021, and 2020, the Company has recorded an uncertain tax position liability exclusive of interest and penalties of $665 thousand and

$461 thousand respectively

which was classified as other long-term liabilities. As of March 31, 2021, and 2020, the Company accrued interest related to uncertain tax positions of $30 thousand and $13 thousand, respectively. These uncertain tax positions would impact the Company’s effective tax rate, if recognized. The Company does not expect that the amounts of uncertain tax positions will change significantly within the next 12 months.

A reconciliation of the Company’s unrecognized tax benefits is below:


	March 31, 2021
	(in thousands)
Uncertain tax position at the beginning of the period	$	581
Additions for uncertain tax position of prior years (foreign exchange and interest)		3
Additions for tax positions of current year		111

Uncertain tax position at the end of the period	$	695

The Company files U.S. federal, various

U.S.

state and Israeli income tax returns. The associated tax filings remain subject to examination by applicable tax authorities for a certain length of time following the tax year to which those filings relate. In the United States and Israel, the 2017 and subsequent tax years remain subject to examination by the applicable taxing authorities as of March 31, 2021.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References + Details

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2021

Accounting Policies [Abstract]

General

b) In 2017, the Company entered into an exclusive worldwide license agreement with respect to AL101 and AL102.

d) The Company has a wholly-owned Israeli subsidiary, Ayala-Oncology Israel Ltd. (the “Subsidiary”), which was incorporated in November 2017.

Initial Public Offering and Related Transactions

S-1

(File

No. 333-236942),

as amended, declared effective by the U.S. Securities and Exchange Commission (the “Commission”) on May 7, 2020.

In connection with the IPO, the Company effected a

one-for-two

(ii) pre-funded

warrants to purchase an aggregate of 1,333,333 shares of its common stock with an exercise price of $0.01 per share (the

“Pre-Funded

Basis of Presentation

10-K

for the year ended December 31, 2020.

Net Loss per Share

The calculation of diluted LPS does not include 1,916,665 Warrants and 915,644 options outstanding to purchase common stock as of March 31 2021.

Newly Issued Accounting Pronouncements

In February 2016, the FASB issued ASU

2016-02—Leases,

requiring the recognition of lease assets and liabilities on the balance sheet. The standard:

right-of-use

In June 2016, the FASB issued ASU

No. 2016-13

2016-13

will have on its consolidated financial statements.

Tax (Tables)

3 Months Ended

Mar. 31, 2021

Income Tax Disclosure [Abstract]

Schedule of Unrecognized Tax Benefits Roll Forward

A reconciliation of the Company’s unrecognized tax benefits is below:


	March 31, 2021
	(in thousands)
Uncertain tax position at the beginning of the period	$	581
Additions for uncertain tax position of prior years (foreign exchange and interest)		3
Additions for tax positions of current year		111

Uncertain tax position at the end of the period	$	695

Significant Accounting Policies - Additional Information (Detail) - USD ($)					3 Months Ended
	Feb. 19, 2021	Jun. 04, 2020	May 12, 2020	May 04, 2020	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Significant Accounting Policies [Line Items]
Shares Issued, Price Per Share		$ 15.00
Proceeds from Issuance Initial Public Offering		$ 52,200,000
Preferred Stock, Shares Outstanding					0
Common stock par value					$ 0.01		$ 0.01
Stockholders' Equity, Reverse Stock Split				In connection with the IPO, the Company effected a one-for-two reverse stock split of its common stock which became effective on May 4, 2020.
Warrant [Member]
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					1,916,665
Common Stock [Member]
Significant Accounting Policies [Line Items]
Conversion of preferred stock					3,715,222
Share-based Payment Arrangement, Option [Member]
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount					915,644	652,187
SeriesA Convertible Preferred Stock [Member]
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount						3,679,778
SeriesB Convertible Preferred Stock [Member]
Significant Accounting Policies [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount						3,750,674
Private Placement Shares And Common Warrants Member [Member] \| 2021 Investors Purchase Agreement [Member]
Significant Accounting Policies [Line Items]
Common stock shares subscribed but not issued	333,333
Common stock par value	$ 0.01
Class of warrants or rights number of shares called by warrants or rights	116,666
Class of warrants or rights number of shares exercise price of warrants or rights	$ 18.10
Common stock shares and warrants subscribed but not issued value	$ 4,999,995.00
Prefunded Warrants [Member] \| 2021 Investors Purchase Agreement [Member]
Significant Accounting Policies [Line Items]
Class of warrants or rights number of shares called by warrants or rights	1,333,333
Class of warrants or rights number of shares exercise price of warrants or rights	$ 0.01
Class of warrants or rights subscribed but not issued	466,666
Class of warrants or rights subscribed but not issued value	$ 19,986,661.67
Over-Allotment Option [Member]
Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues		274,022
IPO [Member]
Significant Accounting Policies [Line Items]
Stock Issued During Period, Shares, New Issues			3,940,689
Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs	1,665,000
Stock Issuance Cost Incurred But Not Yet Paid	$ 290,000

Revenues - Additional Information (Detail) $ in Millions	3 Months Ended
Revenues - Additional Information (Detail) $ in Millions	Mar. 31, 2021 USD ($)
Novartis International Pharmaceutical Agreement [Member] \| Novartis Agreement [Member]
Revenue [Line Items]
Revenue recognised from performance obligation	$ 1.0

Tax - Schedule of Unrecognized Tax Benefits Roll Forward (Detail) $ in Thousands	3 Months Ended
	Mar. 31, 2021 USD ($)
Income Tax Disclosure [Abstract]
Uncertain tax position at the beginning of the period	$ 581
Additions for uncertain tax position of prior years (foreign exchange and interest)	3
Additions for tax positions of current year	111
Uncertain tax position at the end of the period	$ 695

Tax - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Dec. 31, 2020
Income Tax Disclosure [Line Items]
Provision for income taxes	$ 137	$ 70
Federal statutory Income tax rate	21.00%
Uncertain tax positions	$ 695		$ 581
Accrued interest uncertain tax positions	30	13
Other Noncurrent Liabilities [Member]
Income Tax Disclosure [Line Items]
Uncertain tax positions	$ 665	$ 461